1 2 3 4

21 July 2016 EMA/CHMP/CVMP/JEG-3Rs/94436/2014 Committee for Medicinal Products for Human Use (CHMP) Committee for Medicinal Products for Veterinary Use (CVMP)

7

Guidance for individual laboratories for transfer of quality control methods validated in collaborative trials with a view to implementing 3Rs

8

Draft

5 6

Draft agreed by JEG 3Rs

June 2016

Adopted by CVMP for release for consultation

14 July 2016

Adopted by CHMP for release for consultation

21 July 2016

Start of public consultation

29 July 2016

End of consultation (deadline for comments)

31 January 2017

9 Comments should be provided using this template. The completed comments form should be sent to [email protected] 10 Keywords

3Rs, collaborative trials, quality control tests, method transfer, validation

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact

An agency of the European Union

© European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged.

11

Table of contents

12

Executive summary ..................................................................................... 3

13

1. Introduction (background) ...................................................................... 3

14

2. Scope....................................................................................................... 4

15

3. Legal basis .............................................................................................. 4

16 17

4. General features of a collaborative study and its role in method validation .................................................................................................... 4

18

5. Validation of 3Rs methods for regulatory acceptance .............................. 5

19 20

6. Transferring collaborative study validated methods to specific products/laboratories ................................................................................. 5

21

References .................................................................................................. 7

22

Guidance for individual laboratories for transfer of quality control methods validated in collaborative trials with a view to implementing 3Rs EMA/CHMP/CVMP/JEG-3Rs/94436/2014

Page 2/7

23

Executive summary

24

In accordance with Directive 2010/63/EU, the principle of the 3Rs (Replacement, Reduction and

25

Refinement) needs to be considered when selecting approaches for validating quality control tests in

26

laboratories for regulatory testing of human and veterinary medicinal products.

27

Collaborative studies between laboratories may be carried out to introduce new 3Rs methods for

28

regulatory purposes where animal tests have been traditionally used. This guidance aims to facilitate

29

transfer of the new methods validated in such trials with a view to implementing 3Rs for testing in a

30

product specific context in laboratories originally involved in the collaborative trial or in new

31

laboratories.

32

1. Introduction (background)

33

To comply with Directives 2001/83/EC and 2001/82/EC and associated relevant guidelines as well as

34

with the European Pharmacopoeia (Ph. Eur.), quality testing may require the use of animals. Ethical

35

and animal welfare considerations require that animal use is limited as much as possible. In this

36

respect, Directive 2010/63/EU on the protection of animals used for scientific purposes, which is fully

37

applicable to regulatory testing of human and veterinary medicinal products, unambiguously fosters

38

the application of the 3Rs) when considering the choice of methods to be used.

39

Regulatory testing covers all tests performed on starting materials, in process and final product control

40

as required for licensing and final product testing (batch release), where applicable.

41

Various large scale international initiatives and organisations 1 are involved either directly or indirectly

42

in the development, validation and dissemination of 3Rs approaches.

43

Several collaborative studies for quality control have already been carried out to replace, reduce or

44

refine animal testing required for regulatory purposes. In Europe such studies have been organised in

45

the Biologicals Standardisation Programme 2 of the European Directorate for the Quality of Medicines &

46

HealthCare (EDQM, Council of Europe).

47

Collaborative studies provide the opportunity to determine how a test method behaves in different

48

laboratories and with a variety of products. A well-designed study allows an assessment of

49

transferability, repeatability, reproducibility and ultimately whether the method is fit for the intended

50

purpose. It is, however, generally not the goal of a large-scale, collaborative study to carry out product

51

specific validation for individual products. In some cases the data generated in the study may allow

52

suggestions for the establishment of generalised specification against a common standard. However, it

53

may also become apparent that product specific references and/or specifications are the only way

54

forward. These factors and others, as outlined below, will influence the amount of data generation

55

required later for the implementation of the alternative method in an individual laboratory and the

56

extent of validation of the method for a specific product.

1 (e.g. European Directorate for the Quality of Medicines & Healthcare (EDQM), European Partnership for Alternative Approaches to Animal Testing (EPAA), The European Union Reference Laboratory for alternatives to animal testing (EURL ECVAM), The Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM/NICEATM), Japanese Center for the Validation of Alternative Methods (JACVAM), Organisation for Economic Co-operation and Development (OECD), Korean Centre for the Validation of Alternative Methods (KocVAM), World Health Organization (WHO) 2

https://www.edqm.eu/en/Biological-Standardisation-Programme-mission-60.html

Guidance for individual laboratories for transfer of quality control methods validated in collaborative trials with a view to implementing 3Rs EMA/CHMP/CVMP/JEG-3Rs/94436/2014

Page 3/7

57

2. Scope

58

The guideline applies to regulatory testing used for quality control of medicinal products where animals

59

have been traditionally used. It aims to facilitate transfer of quality control methods validated in

60

collaborative trials with a view to implementing 3Rs, for testing in a product specific context.

61

The guideline should be helpful in supporting regulatory applications for variations to existing

62

marketing authorisations as well as new applications.

63

3. Legal basis

64 65

This guideline has to be read in conjunction with:

66



Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the

67

Community code relating to medicinal products for human use (Consolidated version:

68

05/10/2009);

69



70 71

Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to veterinary medicinal products (consolidated version: 18/7/2009);



Directive 2010/63/EU on the protection of animals used for scientific purposes on 3 June 2010.

73

4. General features of a collaborative study and its role in method validation

74

Collaborative studies usually follow a step-wise approach. The number and breakdown of the steps

72

75

depends on the individual case, but generally they include pre-validation steps such as proof of

76

concept and transferability.

77

Proof of concept takes place in one laboratory or a small group of laboratories. Usually it involves one

78

or a small number of products. It includes development of the rationale, protocol development and

79

optimisation to obtain sufficient specificity, sensitivity, repeatability, and reproducibility. Comparison

80

with, but not necessarily correlation to, the existing method is demonstrated [1]. There is evaluation of

81

the need for reagents, controls and reference materials. Also, initial proposals for statistical methods

82

for the design of the collaborative study and to evaluate the results are evaluated.

83

Once proof of concept is established, the method is transferred to at least one additional laboratory.

84

This step determines if the protocol is sufficiently robust to be reproducible and can lead to

85

modifications of the protocol and/or the statistical approach for evaluation of the data. When additional

86

data are needed to compare the new method with an existing animal method, a rationalised strategy

87

at this small-scale stage can also provide a larger data set and help avoid unnecessary repetition of the

88

animal test in a large number of laboratories at the final stage in the large-scale collaborative study.

89

The large-scale collaborative study stage involves many laboratories and includes a range of

90

representative products. At this stage, the protocol should be well defined. Reagents, controls and

91

reference materials should also be defined or at least clearly proposed. The data generated in the

92

large-scale study should reveal the best way forward for setting specifications and possibly suggestions

93

for the specifications themselves. Generally, the outcome of the study allows a decision on whether the

94

proposed method is indeed fit for the intended purpose for a range of products. If the outcome is

95

positive, the method may be considered for integration into a recognised regulatory context (e.g.

96

European Pharmacopoeia (Ph. Eur.) monograph, EMA guidelines or WHO recommendations).

Guidance for individual laboratories for transfer of quality control methods validated in collaborative trials with a view to implementing 3Rs EMA/CHMP/CVMP/JEG-3Rs/94436/2014

Page 4/7

97

Laboratories participating in the study may add, for their own purpose, other related products and/or

98

may include additional in-house validation studies alongside the collaborative study, if needed.

99

Reports (including data, anonymised as appropriate) on all of the different steps should be published

100

and made available to the public, ideally in a peer reviewed scientific journal.

101

5. Validation of 3Rs methods for regulatory acceptance

102

Demonstration of scientific validity is a necessary condition for regulatory acceptance of any test

103

method including methods developed to replace, reduce and refine in vivo tests. For regulatory

104

acceptance at the individual product dossier level, the criteria and scientific principles for test method

105

validation need to be fulfilled and sufficient relevant data submitted. Criteria are defined in different

106

existing guidance documents (e.g. (V)ICH)) and should include:

107

1) Definition of test methodology/standard protocol

108

2) Relevance

109

3) Reliability

110

The level of experimental work required by an individual laboratory to demonstrate method validation

111

is dependent on the approach taken, the starting point and the additional information available from

112

other sources (e.g. collaborative studies).

113

The method validation may involve some level of testing in animals, for example as part of the test

114

method itself (in the case of reduction and refinement) and/or when comparing to the existing method.

115

In order to limit the use of animals and to avoid duplication of work, laboratories are encouraged,

116

wherever possible, to maximise the use of data and information available from other sources in a

117

rationalised strategy.

118

Supporting data can come from a number of sources, including accumulation of product data,

119

published data from individual laboratories, and published study reports from collaborative trials. A

120

laboratory’s own data from participation in a given collaborative study can also be used to support final

121

product specific validation for regulatory acceptance.

123

6. Transferring collaborative study validated methods to specific products/laboratories

124

The amount of additional validation required for transferring/implementing a new alternative method

122

125

will vary case-by-case. Therefore, only high-level guidance on the type of validation and data that

126

might be expected are provided in the following sections. For each of the possible cases below, the

127

choice and suitability of proposed product specifications need to be supported by data generated by

128

the applicant and/or in the collaborative study. This should include use of the method for batches

129

found to be safe and efficacious through clinical studies or equivalent batches released on to the

130

market for routine use. The method should be capable of detecting non-compliant batches.

131

When transferring a method from a collaborative study, if a relevant International Standard (IS) or

132

Biological Reference Preparation (BRP) has been assessed / established in the study, these are used

133

either directly as the assay reference or as part of the establishment and calibration of in-house

134

product-specific reference materials [2]. In house working reference materials are qualified according

135

to ICH guideline Q6B or VICH GL 40. Direct use of a recognised common reference such as an IS or

136

BRP will reduce the amount of in-house validation required. It would normally suffice to confirm the

Guidance for individual laboratories for transfer of quality control methods validated in collaborative trials with a view to implementing 3Rs EMA/CHMP/CVMP/JEG-3Rs/94436/2014

Page 5/7

137

suitability of the reference to the product under study either through evidence from the collaborative

138

study or through new studies by the applicant as appropriate

139

By implementing methods validated through collaborative studies, various scenarios can be possible.

140

The main different types of possible cases are summarised in Table 1.

141

Table 1. Guidance on the extent of validation needed is reported for each circumstance in the column

142

“Action”. Case

Scenario

Action

1

The laboratory participated in the

No additional method validation is normally

collaborative study and intends to test a

needed provided the method procedure is aligned

product that was included in that study.

with the method used in the collaborative study and the results from the laboratory were satisfactory. Supporting documentation demonstrating the transfer should be provided. The laboratory’s data from the collaborative study may be used as part of the supporting documentation.

2

The laboratory participated in the

Supporting documentation demonstrating the

collaborative study and intends to test a

transfer should be provided. The laboratory’s

product included in that study but one or

data from the collaborative study may be used as

more changes have been introduced to the

part of the supporting documentation.

test protocol compared to the one used in the collaborative study.

In addition data should be presented showing that the modification(s) to the validated method do not have an impact on performance of the method and that validity criteria are met. If an impact is observed this should be evaluated and any revision to validity and/or acceptance criteria should be supported by appropriate validation data.

3.1

The laboratory participated in the

Supporting documentation demonstrating the

collaborative study and intends to test an

transfer should be provided. The laboratory’s

active substance in a product related to

data from the collaborative study may be used as

one that was included in that study (for

part of the supporting documentation.

example a product using the same manufacturing process that may contain fewer or additional antigens, a different adjuvant or excipients).

3.2

The laboratory participated in the collaborative study and intends to test a related active substance in a product from a different manufacturer or manufacturing process, or newly developed product.

In addition data should be presented showing that the validated method is suitable for testing the product in question and that there is no impact on method performance or validity criteria. If an impact is observed this should be evaluated and any revision to validity and/or acceptance criteria should be supported by appropriate validation data.

Guidance for individual laboratories for transfer of quality control methods validated in collaborative trials with a view to implementing 3Rs EMA/CHMP/CVMP/JEG-3Rs/94436/2014

Page 6/7

4

The laboratory did not participate in the

The method must be successfully transferred to

study and intends to test a product that

the testing laboratory (for example by testing

was included in the study.

reference and or control materials, if available, used in the collaborative study to confirm adequate method performance within the laboratory). If modifications are introduced to the test protocol data should be presented showing that they do not have an impact on performance of the method and that validity criteria are met. If an impact is observed this should be evaluated and any revision to validity and/or acceptance criteria should be supported by appropriate validation data.

5

The laboratory did not participate in the

The method must be successfully transferred to

collaborative study and intends to test a

the testing laboratory (for example by testing

product that was not included in the study.

reference and or control materials, if available, used in the collaborative study to confirm adequate method performance within the new laboratory). If modifications are introduced to the test protocol data should be presented showing that they do not have an impact on performance of the method and that validity criteria are met. Data should be presented showing that the method is suitable for testing the product in question and that there is no impact on method performance or validity criteria. If an impact is observed this should be evaluated and any revision to validity and/or acceptance criteria should be supported by appropriate validation data.

143

References

144

[1]

5.2.14. Substitution of in vivo method(s) by in vitro method(s) for the quality control of

145

vaccine, Pharmeuropa, 2016 28(2), Pages 1–4 (to be replaced by reference to Ph.Eur. 9th

146

Edition).

147 148

[2]

P. Castle, Reference standards for vaccine-producing laboratories, Rev. sci. tech. Off. Int. Epiz., 1998, 17 (2), 585-591.

Guidance for individual laboratories for transfer of quality control methods validated in collaborative trials with a view to implementing 3Rs EMA/CHMP/CVMP/JEG-3Rs/94436/2014

Page 7/7

Draft Guidance for individual laboratories for transfer of quality control ...

Jul 21, 2016 - the application of the 3Rs) when considering the choice of methods to ... in the development, validation and dissemination of 3Rs approaches.

133KB Sizes 4 Downloads 243 Views

Recommend Documents

Guidance for individual laboratories for transfer of quality control ...
Nov 9, 2017 - transfer and acceptance of the new methods validated in such trials with a view to implementing 3Rs ... respect, Directive 2010/63/EU on the protection of animals used for scientific purposes, which is fully .... published data from ind

Overview of comments received on Guidance for individual ...
Overview of comments received on 'Guidance for individual laboratories for transfer of quality control methods validated in collaborative trials with a view to.

Overview of comments received on Guidance for individual ...
Nov 9, 2017 - We are not in a position to give more detailed advice on the quantity of data. When more experience is gained it could be considered to update the Guideline with an annex giving examples. 2. IFAH-Europe has no comments to the draft Guid

Guidance for CRP Second Call - DRAFT - Version 2 - CGSpace - cgiar
Dec 20, 2013 - all current CRP contracts, and to initiate a second call two-stage ... Increased internal coherence for some CRPs, reducing the number of ...

Guidance for CRP Second Call - DRAFT - Version 2 - CGIAR Library
Dec 20, 2013 - all current CRP contracts, and to initiate a second call two-stage proposal ... End-February, 2014: Release of Version 3 of the draft Guidance ...... balanced way all three dimensions of sustainable development and their.

Guidance for CRP Second Call - DRAFT - Version 2 - CGIAR Library
Dec 20, 2013 - accountability framework that best positions IEA to carry out the ex-post .... policy, new soil management practice,, newsletter, tool, website, conference, etc. ..... Capacity building at the proof of concept and pilot phase may inclu

Guidance for CRP Second Call - DRAFT - Version 2 - CGSpace - CGIAR
Dec 20, 2013 - (ISPC, CRP leaders, FC, Center DGs and Board Chairs, CB). ...... coordination of activities without any transfer of funding, while others may ...... 1(title), for capacity strengthening of development partners along the value chain.

Quality of Service Routing and Admission Control for ...
1. Quality of Service Routing and Admission Control for Mobile. Ad-hoc Networks with a Contention-based MAC Layer. L. Hanzo (II.) and R. Tafazolli. Centre for ...

Presentation - Approaches for quality control testing of LSD vaccines
LSD Vaccine: How much quality information or guarantees do you have now? -> Trust ... -Reproductive Performance: use in pregnant animals. -Dissemination of ...

Guidance for Industry - FDA
FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Rather ... FDA recommends a quality risk management approach to clinical trials and is considering the ..... 27 See guidances for industry: Part

Draft concept paper on guidance for the collection of data on ...
Jul 13, 2016 - The lessons learnt during the trial on the collection of antimicrobial .... physical meeting will take place in 2016 and Adobe Connect meetings ...

Social Media Draft Guidance Webinar - FDA
Jul 10, 2014 - Jean-Ah Kang – Internet/Social Media Platforms with Character ... educational grant) and has no control or influence on the third-party site. 10 ...

DRAFT FORMS IRO DRAFT RULES FOR CHAPTER X OF ... - Taxmann
Digital signature of the authorizing officer. This e-form is hereby approved/rejected ... (Name, Signature and. Seal of the Auditor). Attachments: 1 Optional ...

Guidance for Industry: Recommendations for Blood ... - FDA
Nov 16, 2010 - proposed in the Pandemic (H1N1) 2009 Virus Draft Guidance, the finalized recommendations are applicable regardless of the existence of a pandemic or other emergency situation. This guidance is intended for establishments that manufactu

Working Draft For Discussion Purposes Only Draft of model ...
Announcement is submitted to the DPL Website. 1.7 “DPL User” means an Entity that: (a) has committed to offer a License to its Patents and any Patents it may ...

pdf-1496\quality-control-manual-for-citrus-processing-plants-volume ...
Download. Connect more ... or edit this item. pdf-1496\quality-control-manual-for-citrus-processing-pl ... l-systems-important-volatiles-shelf-life-specialty-a.pdf.